附錄圖表



將人類乳癌細胞 MCF-7 利用設計胜肽 peptide 1 (Fmoc-Glu-Tyr-Aib- Asn-NH_2) 序列濃度(DMSO, 0, 1, 25, 50, 75,與 100 µM) 與 Doxorubicin 處理 24 小時之存活率

Human breast cancer cells MCF-7 were treated with DMSO、 0、 1、 25、 50、 75 and 100 µM of design peptide 1 (Fmoc-Glu-Tyr-Aib-Asn-NH_2) and Doxorubicin as positive control for 24 hours. Cell viability was determined by MTT assay.

＊ Significant different at $p < 0.05$ level compared with medium control.
Data are presented as the mean ± SD (n＝3)



將人類乳癌細胞 MCF-7 利用設計胜肽 peptide 1 (Fmoc-Glu-Tyr-Aib- Asn- NH_2) 序列濃度(DMSO、 0、 1、 25、 50、 75 and 100 µM) 與 Doxorubicin 處理 48 小時之存活率

Human breast cancer cells MCF-7 were treated with DMSO, 0, 1, 25, 50, 75, and 100 µM of design peptide 1 (Fmoc-Glu-Tyr-Aib-Asn-NH_2) and Doxorubicin as positive control for 48 hours. Cell viability was determined by MTT assay.

＊ Significant different at $p < 0.05$ level compared with medium control.
Data are presented as the mean ± SD (n＝3)



將人類乳癌細胞 MCF-7 利用設計胜肽 peptide 1 (Fmoc-Glu-Tyr-Aib- Asn- NH_2) 序列濃度(DMSO、 0、 1、 25、 50、 75 and 100 μM) 與 Doxorubicin 處理 72 小時之存活率

Human breast cancer cells MCF-7 were treated with DMSO, 0, 1, 25, 50, 75, and 100 μM of design peptide 1 (Fmoc-Glu-Tyr-Aib-Asn-NH_2) and Doxorubicin as positive control for 72 hours. Cell viability was determined by MTT assay.

＊ Significant different at $p < 0.05$ level compared with medium control.
Data are presented as the mean ± SD (n＝3)



將人類乳癌細胞 MDA-MB-453 利用設計胜肽 peptide 1 (Fmoc-Glu-Tyr-Aib-Asn-NH_2) 序列濃度(DMSO、 0、 1、 25、 50、 75 and 100 μM) 與 Doxorubicin 處理 24 小時之存活率

Human breast cancer cells MDA-MB-453 were treated with DMSO, 0, 1, 25, 50, 75, and 100 μM of design peptide 1 (Fmoc-Glu-Tyr-Aib-Asn-NH_2) and Doxorubicin as positive control for 24 hours. Cell viability was determined by MTT assay.

＊ Significant different at $p < 0.05$ level compared with medium control.
Data are presented as the mean ± SD (n＝3)



將人類乳癌細胞 MDA-MB-453 利用設計胜肽 peptide 1 (Fmoc-Glu-Tyr-Aib-Asn-NH_2) 序列濃度(DMSO、 0、 1、 25、 50、 75 and 100 μM) 與 Doxorubicin 處理 48 小時之存活率

Human breast cancer cells MDA-MB-453 were treated with DMSO, 0, 1, 25, 50, 75, and 100 μM of design peptide 1 (Fmoc-Glu-Tyr-Aib-Asn-NH_2) and Doxorubicin as positive control for 48 hours. Cell viability was determined by MTT assay.

＊ Significant different at $p < 0.05$ level compared with medium control.
Data are presented as the mean ± SD (n＝3)



將人類乳癌細胞 MDA-MB-453 利用設計胜肽 peptide 1 (Fmoc-Glu-Tyr-Aib-Asn-NH_2) 序列濃度(DMSO、 0、 1、 25、 50、 75 and 100 μM) 與 Doxorubicin 處理 48 小時之存活率

Human breast cancer cells MDA-MB-453 were treated with DMSO, 0, 1, 25, 50, 75, and 100 μM of design peptide 1 (Fmoc-Glu-Tyr-Aib-Asn-NH_2) and Doxorubicin as positive control for 48 hours. Cell viability was determined by MTT assay.

＊ Significant different at $p < 0.05$ level compared with medium control.
Data are presented as the mean ± SD (n＝3)



將人類乳癌細胞 MCF-7 利用設計胜肽 peptide 2 (Arg-Gly-Asp-Glu-Tyr-Aib-Asn-Arg-Gly-Asp-NH_2) 序列濃度(RGD、 0、 25、 50、 75 與 100 μM) 與 Doxorubicin 處理 24 小時之存活率

Human breast cancer cells MCF-7 were treated with 0,25, 50, 75, and 100 μM of design peptide 2 (Arg-Gly-Asp-Glu-Tyr-Aib-Asn-Arg-Gly-Asp-NH_2) and Doxorubicin as positive control, the peptide sequence of RGD as negative control for 24 hours. Cell viability was determined by MTT assay.

＊ Significant different at $p < 0.05$ level compared with medium control.
Data are presented as the mean ± SD (n＝3)



將人類乳癌細胞 MCF-7 利用設計胜肽 peptide 2 (Arg-Gly-Asp-Glu-Tyr-Aib-Asn-Arg-Gly-Asp-NH_2) 序列濃度(RGD、 0、 25、 50、 75 與 100 μM) 與 Doxorubicin 處理 48 小時之存活率

Human breast cancer cells MCF-7 were treated with 0,25, 50, 75, and 100 μM of design peptide 2 (Arg-Gly-Asp-Glu-Tyr-Aib-Asn-Arg-Gly-Asp-NH_2) and Doxorubicin as positive control, the peptide sequence of RGD as negative control for 48 hours. Cell viability was determined by MTT assay.

＊ Significant different at $p < 0.05$ level compared with medium control.
Data are presented as the mean ± SD (n＝3)



將人類乳癌細胞 MCF-7 利用設計胜肽 peptide 2 (Arg-Gly-Asp-Glu-Tyr-Aib-Asn-Arg-Gly-Asp-NH_2) 序列濃度(RGD、 0、 25、 50、 75 與 100 μM) 與 Doxorubicin 處理 72 小時之存活率

Human breast cancer cells MCF-7 were treated with 0,25, 50, 75, and 100 μM of design peptide 2 (Arg-Gly-Asp-Glu-Tyr-Aib-Asn-Arg-Gly-Asp-NH_2) and Doxorubicin as positive control, the peptide sequence of RGD as negative control for 72 hours. Cell viability was determined by MTT assay.

＊ Significant different at $p < 0.05$ level compared with medium control.
Data are presented as the mean ± SD (n＝3)



將人類乳癌細胞 MDA-MB-453 利用設計胜肽 peptide 2 (Arg-Gly-Asp-Glu-Tyr-Aib-Asn-Arg-Gly-Asp-NH_2) 序列濃度(RGD、 0、 50、 75 與 100 μM) 與 Doxorubicin 處理 24 小時之存活率

Human breast cancer cells MDA-MB-453 were treated with 0, 50, 75, and 100 μM of design peptide 2 (Arg-Gly-Asp-Glu-Tyr-Aib-Asn-Arg-Gly-Asp-NH_2) and Doxorubicin as positive control, the peptide sequence of RGD as negative control for 24 hours. Cell viability was determined by MTT assay.

＊ Significant different at $p < 0.05$ level compared with medium control.
Data are presented as the mean ± SD (n＝3)



將人類乳癌細胞 MDA-MB-453 利用設計胜肽 peptide 2 (Arg-Gly-Asp-Glu-Tyr-Aib-Asn-Arg-Gly-Asp-NH_2) 序列濃度(RGD、 0、 50、 75 與 100 μM) 與 Doxorubicin 處理 48 小時之存活率

Human breast cancer cells MDA-MB-453 were treated with 0, 50, 75, and 100 μM of design peptide 2 (Arg-Gly-Asp-Glu-Tyr-Aib-Asn-Arg-Gly-Asp-NH_2) and Doxorubicin as positive control, the peptide sequence of RGD as negative control for 48 hours. Cell viability was determined by MTT assay.

＊ Significant different at $p < 0.05$ level compared with medium control.
Data are presented as the mean ± SD (n＝3)



將人類乳癌細胞 MDA-MB-453 利用設計胜肽 peptide 2 (Arg-Gly-Asp-Glu-Tyr-Aib-Asn-Arg-Gly-Asp-NH_2) 序列濃度(RGD、 0、 50、 75 與 100 μM) 與 Doxorubicin 處理 72 小時之存活率

Human breast cancer cells MDA-MB-453 were treated with 0, 50, 75, and 100 μM of design peptide 2 (Arg-Gly-Asp-Glu-Tyr-Aib-Asn-Arg-Gly-Asp-NH_2) and Doxorubicin as positive control, the peptide sequence of RGD as negative control for 72 hours. Cell viability was determined by MTT assay.

＊ Significant different at $p < 0.05$ level compared with medium control.
Data are presented as the mean ± SD (n＝3)